loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Neflamapimod

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Neflamapimod

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    CervoMed To Present Neflamapimod Biomarker Data In DLB At AAIC 2024
    CervoMed To Present Neflamapimod Biomarker Data In DLB At AAIC 2024

    29 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/29/2920251/0/en/CervoMed-Announces-Presentation-at-AAIC-2024-on-Plasma-Biomarker-Data-That-Are-Consistent-with-Neflamapimod-Impacting-the-Underlying-Disease-Process-in-Patients-with-Dementia-with-.html

    GLOBENEWSWIRE
    29 Jul 2024
    Share Share
    CervoMed To Host KOL Event On Neflamapimod For Lewy Body Dementia
    CervoMed To Host KOL Event On Neflamapimod For Lewy Body Dementia

    11 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/11/2911837/0/en/CervoMed-to-Host-Virtual-KOL-Event-on-Neflamapimod-for-Dementia-with-Lewy-Bodies-on-July-23-2024.html

    GLOBENEWSWIRE
    11 Jul 2024
    Share Share
    CervoMed Completion Pha 2b RewinD-LB Clinical Trial of Neflamapimod
    CervoMed Completion Pha 2b RewinD-LB Clinical Trial of Neflamapimod

    11 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/11/2896702/0/en/CervoMed-Announces-Completion-of-Enrollment-in-Phase-2b-RewinD-LB-Clinical-Trial-of-Neflamapimod-for-the-Treatment-of-Patients-with-Dementia-with-Lewy-Bodies.html

    GLOBENEWSWIRE
    11 Jun 2024
    Share Share
    EIP Pharma Announces First Patient Dosed in Ph 2b Trial Evaluating Neflamapimod
    EIP Pharma Announces First Patient Dosed in Ph 2b Trial Evaluating Neflamapimod

    14 Aug 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/eip-pharma-announces-first-patient-dosed-in-rewind-lb-phase-2b-clinical-trial-evaluating-neflamapimod-in-dementia-with-lewy-bodies-301899140.html

    PR NEWSWIRE
    14 Aug 2023
    Share Share
    EIP Pharma Publishes Data of Preclinical and Phase 2a Results for Neflamapimod
    EIP Pharma Publishes Data of Preclinical and Phase 2a Results for Neflamapimod

    21 Sep 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220921005203/en

    BUSINESSWIRE
    21 Sep 2022
    Share Share
    Lantern Pharma Announces Abstract on Effectiveness of LP-284 in ASH
    Lantern Pharma Announces Abstract on Effectiveness of LP-284 in ASH

    04 Nov 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/lantern-pharma-announces-abstract-on-effectiveness-of-lp-284-in-hematologic-cancers-accepted-for-presentation-at-the-63rd-american-society-of-hematology-ash-annual-meeting-301416654.html

    PRNEWSWIRE
    04 Nov 2021
    Share Share